Last reviewed · How we verify
Phase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD)
The purpose of this study is to determine whether recombinant human Erythropoietin (EPOrh) is safe in the treatment of patients with Parkinson's Disease.
Details
| Lead sponsor | International Center for Neurological Restoration, Cuba |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 10 |
| Start date | 2008-08 |
| Completion | 2009-05 |
Conditions
- Parkinson Disease
Interventions
- Erythropoietin human recombinant (EPOrh)
Primary outcomes
- safety assessment measured by the absence of adverse events — weeks 1 to 5, 6, 12, 23 and 35
Countries
Cuba